Downloads: 64

Files in This Item:
File Description SizeFormat 
s41598-018-34193-1.pdf5.19 MBAdobe PDFView/Open
Title: Using patient-derived iPSCs to develop humanized mouse models for chronic myelomonocytic leukemia and therapeutic drug identification, including liposomal clodronate
Authors: Taoka, Kazuki
Arai, Shunya
Kataoka, Keisuke
Hosoi, Masataka
Miyauchi, Masashi
Yamazaki, Sho
Honda, Akira
Aixinjueluo, Wei
Kobayashi, Takashi
Kumano, Keiki
Yoshimi, Akihide
Otsu, Makoto
Niwa, Akira  kyouindb  KAKEN_id
Nakahata, Tatsutoshi
Nakauchi, Hiromitsu
Kurokawa, Mineo
Author's alias: 丹羽, 明
中畑, 龍俊
Issue Date: 26-Oct-2018
Publisher: Springer Nature America, Inc
Journal title: Scientific reports
Volume: 8
Thesis number: 15855
Abstract: Chronic myelomonocytic leukemia (CMML) is an entity of myelodysplastic syndrome/myeloproliferative neoplasm. Although CMML can be cured with allogeneic stem cell transplantation, its prognosis is generally very poor due to the limited efficacy of chemotherapy and to the patient’s age, which is usually not eligible for transplantation. Comprehensive analysis of CMML pathophysiology and the development of therapeutic agents have been limited partly due to the lack of cell lines in CMML and the limited developments of mouse models. After successfully establishing patient’s derived disease-specific induced pluripotent stem cells (iPSCs) derived from a patient with CMML, we utilized these CMML-iPSCs to achieve hematopoietic re-differentiation in vitro, created a humanized CMML mouse model via teratomas, and developed a drug-testing system. The clinical characteristics of CMML were recapitulated following hematopoietic re-differentiation in vitro and a humanized CMML mouse model in vivo. The drug-testing system using CMML-iPSCs identified a MEK inhibitor, a Ras inhibitor, and liposomal clodronate as potential drugs for treating CMML. Clodronate is a drug commonly used as a bisphosphonate for osteoporosis. In this study, the liposomalization of clodronate enhanced its effectiveness in these assays, suggesting that this variation of clodronate may be adopted as a repositioned drug for CMML therapy.
Rights: © The Author(s) 2018. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
URI: http://hdl.handle.net/2433/234928
DOI(Published Version): 10.1038/s41598-018-34193-1
PubMed ID: 30367142
Appears in Collections:Journal Articles

Show full item record

Export to RefWorks


Export Format: 


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.